Kim I, et al. - Researchers assessed the impact of metabolic syndrome (MS) on clinical outcomes in young adults (<50 years) with acute myocardial infarction (AMI). MS was present in almost half of young AMI patients. The highest incidence of re-AMI was seen in young AMI patients with MS vs the other groups. Young patients with MS require AMI management via aggressive pharmacological intervention and lifestyle modification.

Methods

• A total of 2,082 patients with AMI who underwent percutaneous coronary intervention were retrospectively analyzed.
• The term “young” was defined as age <50 years.

Results

• The prevalence of patients in this cohort aged <50 years was 18.4%, and of those, 43.4% had MS.
• In old patients without MS, the reported incidence of long-term major adverse cardiac and cerebral events (MACCEs) was highest (30.7% in young patients with MS, 22.2% in young patients without MS, 38.4% in old patients with MS, and 40.4% in old patients without MS, p <0.001).
• The highest recurrent AMI (re-AMI) was observed in young AMI patients with MS (4.8%, 1.4%, 2.1%, 1.5%, p=0.035, respectively).
• A tendency to have highest incidence of re-AMI was noted in young AMI patients with MS in Kaplan-Meier curve (p=0.050).
• The presence of MS in young AMI patients was identified as an independent predictor of 6-year MACCE (HR: 3.320; 95% CI: 1.073 to 10.283; p=0.038) and re-AMI (HR: 7.782; 95% CI: 1.290 to 45.298; p=0.022).